Quest Diagnostics (DGX) Tops Q1 EPS by 18c, Beats on Revenue; Offers FY24 Guidance

Quest Diagnostics (NYSE: DGX) reported Q1 EPS of $2.04, $0.18 better than the analyst estimate of $1.86. Revenue for the quarter came in at $2.37 billion versus the consensus estimate of $2.29 billion.

GUIDANCE:

Quest Diagnostics sees FY2024 EPS of $8.72-$8.97, versus the consensus of $8.75. Quest Diagnostics sees FY2024 revenue of $9.4-9.48 billion, versus the consensus of $9.4 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• S&P Global releases recast financials after Mobility spin-off
• Morgan Stanley Resumes Gap, Inc. (GAP) at Equalweight